SANOFI PASTEUR
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Subsidiary
- Established
- 1990-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.sanofipasteur.com
Clinical Trials
423
Active:67
Completed:329
Trial Phases
5 Phases
Phase 1:86
Phase 2:81
Phase 3:143
+2 more phases
Drug Approvals
34
SFDA:17
NMPA:8
PHILIPPINES:7
+2 more agencies
Drug Approvals
Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) vaccine and Haemophilus type b conjugate vaccine, adsorbed
- Product Name
- 潘太欣
- Approval Number
- 国药准字SJ20150034
- Approval Date
- Aug 13, 2020
NMPA
Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) vaccine and Haemophilus type b conjugate vaccine, adsorbed
- Product Name
- 潘太欣
- Approval Number
- 国药准字SJ20150033
- Approval Date
- Aug 13, 2020
NMPA
Haemophilus Type b Conjugate Vaccine
- Product Name
- 安尔宝
- Approval Number
- 国药准字J20140173
- Approval Date
- May 25, 2020
NMPA
Haemophilus Type b Conjugate Vaccine
- Product Name
- 安尔宝
- Approval Number
- S20140013
- Approval Date
- Apr 12, 2020
NMPA
Haemophilus Type b Conjugate Vaccine
- Product Name
- 安尔宝
- Approval Number
- S20140014
- Approval Date
- Apr 12, 2020
NMPA
POLIOMYELITIS VACCINE (INACTIVATED)
- Product Name
- 爱宝惟
- Approval Number
- 国药准字J20140171
- Approval Date
- Sep 16, 2019
NMPA
POLIOMYELITIS VACCINE (INACTIVATED)
- Product Name
- 爱宝惟
- Approval Number
- S20140062
- Approval Date
- Aug 8, 2019
NMPA
POLIOMYELITIS VACCINE (INACTIVATED)
- Product Name
- 爱宝惟
- Approval Number
- S20140063
- Approval Date
- Aug 8, 2019
NMPA
Clinical Trials
Distribution across different clinical trial phases (374 trials with phase data)• Click on a phase to view related trials
Phase 3
143 (38.2%)Phase 1
86 (23.0%)Phase 2
81 (21.7%)Phase 4
62 (16.6%)Not Applicable
2 (0.5%)Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne
- First Posted Date
- 2025-06-10
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 120
- Registration Number
- NCT07013747
- Locations
- 🇺🇸
Encino Research Center- Site Number : 8400008, Encino, California, United States
🇺🇸DelRicht Research- Site Number : 8400003, New Orleans, Louisiana, United States
Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea
Recruiting
- Conditions
- Hepatitis BHaemophilus Influenzae Type b Immunisation
- Interventions
- Biological: DTaP-IPV-Hep B-PRP-T combined vaccine
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 690
- Registration Number
- NCT06793826
- Locations
- 🇰🇷
Investigational Site Number : 002, Cheonan, Korea, Republic of
🇰🇷Investigational Site Number : 001, Seoul, Korea, Republic of
Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents
- First Posted Date
- 2025-02-20
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 1252
- Registration Number
- NCT06838000
- Locations
- 🇺🇸
Site #8400010, Binghamton, New York, United States
Repeated Cross Sectional Surveillance Study To Determine the Respiratory Syncytial Virus (RSV) Immunization Rates in German Infants
Active, not recruiting
- Conditions
- Respiratory Syncytial Virus Immunization
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 2400
- Registration Number
- NCT06824207
Repeated Cross Sectional Surveillance Study To Determine the Influenza Vaccination Rates in German Participants
Active, not recruiting
- Conditions
- Influenza Immunization
- First Posted Date
- 2025-01-30
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 5000
- Registration Number
- NCT06800885
- Prev
- 1
- 2
- 3
- 4
- 5
- 75
- Next
News
Saint Louis University Launches Phase 1 Trial for Investigational West Nile Virus Vaccine
Saint Louis University's Center for Vaccine Development will enroll up to 30 healthy adult volunteers in a Phase 1 clinical trial to evaluate the safety and immune response of an updated investigational West Nile virus vaccine.